ロード中...
Anti-CD20 monoclonal antibodies: reviewing a revolution
Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice. Additionally, the potent efficacy of these agents in depleting the B cell compartment...
保存先:
| 出版年: | Hum Vaccin Immunother |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6343614/ https://ncbi.nlm.nih.gov/pubmed/30096012 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1508624 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|